Lupin launches generic Aricept tablets in the US
Mumbai/ Baltimore, Mar 31 (IBNS) Mumbai-based Lupin Limited (Lupin), a transnational pharmaceutical company producing and developing a wide range of branded and generic formulations, biotechnology products and APIs globally, announced on Thursday that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Donepezil Hydrochloride Tablets, 23 mg having received approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of Eisai Inc's AriceptÂ® Tablets, 23mg.
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. works in the area of generic medicines and branded formulations.
Lupin's Donepezil Hydrochloride Tablets, 23 mg are the AB rated generic equivalent of Eisai Inc's Aricept® Tablets, 23mg. It is indicated for the treatment of dementia of the Alzheimer's type.
Aricept® had US sales of USD 47.1 million (IMS MAT December 2015).
Time to separate interests from Tata Group, says Mistry family Tue, Sep 22 2020
Event industry apex body EEMA organises workshop for stakeholders for holding safe programmes Tue, Sep 22 2020
Ducati launches its first BS6 Scrambler Tue, Sep 22 2020
Tata Motors rolls out the 3,00,000th Tiago from its Sanand plant Tue, Sep 22 2020
IndiGo operates its maiden cargo flight to Chittagong Tue, Sep 22 2020
Maruti Suzuki moves down by 3.15 pc to Rs 6413.85 Tue, Sep 22 2020
Indian Market: Sensex down 300.06 pts Tue, Sep 22 2020
Indian Rupee down 17 paise against USD Tue, Sep 22 2020
Tata Power signs PPA with Apollo Gleneagles Hospital Tue, Sep 22 2020
HDFC Life, Yes Bank enter into Corporate Agency (CA) arrangement Tue, Sep 22 2020